Cyclin-dependent kinase inhibitor 1B (CDKN1B) (CDKN1B)

Cyclin-dependent kinase inhibitor 1B (CDKN1B), also known as p27Kip1, is a critical protein that regulates the cell cycle by inhibiting the transition from the G1 to the S phase (UniProt: P46527). It functions by binding to and inactivating cyclin-dependent kinase (CDK) complexes, such as Cyclin E-CDK2 and Cyclin D-CDK4, thereby preventing premature DNA replication (NCBI Gene: 1027). In many human cancers, CDKN1B acts as a tumor suppressor, and its downregulation—often through accelerated proteasomal degradation by the Skp2 ubiquitin ligase—is associated with increased tumor aggressiveness and poor prognosis (PubMed: 21135111). While germline mutations in the CDKN1B gene are the primary cause of Multiple Endocrine Neoplasia type 4 (MEN4), most therapeutic interest focuses on restoring its levels in sporadic cancers (PubMed: 17023922). Current pharmacological strategies include the use of proteasome inhibitors like bortezomib to stabilize the protein, experimental Skp2 inhibitors, and novel mRNA-based therapies designed to reintroduce functional CDKN1B into malignant cells. Additionally, experimental knockdown of CDKN1B mRNA using siRNAs is being investigated as a method to stimulate the regeneration of specialized cells, such as those in the inner ear, by forcing quiescent cells back into the cell cycle (PubMed: 23539124).

Other names

p27KIP1p27Kip1MEN4MEN1BCDKN4

Stabilization of p27 protein via inhibition of the SCF-Skp2 ubiquitin ligase complex or the proteasome; exogenous delivery of CDKN1B mRNA to restore tumor suppressor function; siRNA-mediated knockdown to promote cellular regeneration.